Tabll Ashraf, El Abd Yasmine, El Din Noha G Bader, El Shenawy Reem, Abdelhafez Tawfeek H, El Awady Mostafa, El-Mohamady Hanan, Viazov Sergei
Microbial Biotechnology, National Research Center, Giza, Egypt.
NAMRU-3, Cairo, Egypt.
Hum Antibodies. 2013;22(3-4):55-65. doi: 10.3233/HAB-140271.
We aimed to establish Human cell lines producing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus (HCV). Two protocols for EBV immortalization of CD22⁺ cells separated from HCV positive patients were used; 1) Immortalization with 100% EBV only, 2) immortalization by 30% EBV and CPG2006. Immortalization was checked microscopically and verified by screening the culture supernatant for antibody production using dot blot and ELISA analysis. ELISA plates were coated by HCV E1/E2 derived from cell lysate transfected by plasmid expressed HCV E1/E2. Also we tested the reactivity of human antibodies based on ELISA plates coating with one linear peptides derived from HCV E1 (a.a 315-319) and two peptides derived from HCV E2 (a.a 412-419) and (a.a 517-530). Neutralization activity was measured using H77C HCV retroviral pseudoparticles (HCVpp). Fifteen clones secreting human immunoglobulin G against HCV E1/E2 protein were isolated. Results of ELISA plates coated with HCV peptides showed that one antibody was binding to E2 peptide (a.a 517-530), and two antibodies binding to HCV E2 peptide (a.a 412-419). The three generated antibodies showed extremely neutralization activity against HCV pp. The three human antibodies were IgG3 and IgG2. These antibodies may be useful for passive immunotherapy of HCV infection.
我们旨在建立能够产生针对丙型肝炎病毒(HCV)包膜E1/E2蛋白的人单克隆抗体的人细胞系。采用了两种对从HCV阳性患者分离出的CD22⁺细胞进行EBV永生化的方案;1)仅用100%EBV进行永生化,2)用30%EBV和CPG2006进行永生化。通过显微镜检查来检查永生化情况,并通过斑点印迹和ELISA分析筛选培养上清液中的抗体产生情况来进行验证。ELISA板用源自转染表达HCV E1/E2的质粒的细胞裂解物的HCV E1/E2包被。我们还基于用源自HCV E1(氨基酸315 - 319)的一种线性肽以及源自HCV E2(氨基酸412 - 419)和(氨基酸517 - 530)的两种肽包被的ELISA板来测试人抗体的反应性。使用H77C HCV逆转录病毒假颗粒(HCVpp)来测量中和活性。分离出了15个分泌针对HCV E1/E2蛋白的人免疫球蛋白G的克隆。用HCV肽包被的ELISA板的结果表明,一种抗体与E2肽(氨基酸517 - 530)结合,两种抗体与HCV E2肽(氨基酸412 - 4)结合。产生的这三种抗体对HCV pp显示出极强的中和活性。这三种人抗体为IgG3和IgG2。这些抗体可能对HCV感染的被动免疫治疗有用。